Oxomemazine Sans Sucre Cristers (Oxomemazine)

Oxomemazine exerts its effect by competitively antagonising histamine H1 receptors in peripheral tissues and the central nervous system. This blockade prevents histamine‑induced vasodilation, increased vascular permeability and sensory nerve activation, which are responsible for the classic signs of allergy. The central H1 antagonism also produces a mild sedative effect.

The appropriate dose of oxomemazine is determined by the prescribing clinician based on the patient’s age, weight, severity of symptoms and overall health status. Dosage recommendations are provided in the product’s prescribing information and should be followed exactly as directed by a qualified healthcare professional.

Oxomemazine should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus, as safety data are limited. During breastfeeding, the drug may be excreted in milk; therefore, a risk‑benefit assessment is required, and alternative treatments may be considered when possible.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Oxomemazine belongs to the first‑generation antihistamine class, which generally provides effective symptom relief but is associated with higher sedation and anticholinergic effects compared with second‑generation agents such as cetirizine or loratadine. Choice of therapy depends on clinical needs, patient tolerance for sedation and the risk‑benefit profile for each individual.

Oxomemazine tablets should be stored at temperatures below 25 °C, in their original packaging, protected from moisture and direct sunlight. Ensure the container is tightly closed to maintain product stability throughout its shelf life.

Oxomemazine is administered orally, typically as a tablet taken with or without food, according to the prescriber’s instructions. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically advised by a healthcare professional.

Serious adverse reactions, although rare, include cardiac arrhythmias, severe allergic responses (anaphylaxis), hepatotoxicity, extrapyramidal symptoms and hematologic abnormalities such as unexplained bruising or low blood counts. Patients should seek immediate medical attention if they experience any of these symptoms.

Oxomemazine is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. It should also be avoided in patients taking mono‑amine oxidase inhibitors (MAOIs) or those with conditions that could be exacerbated by its sedative or anticholinergic properties, unless directed by a qualified clinician.